专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5958010A Systems and methods for monitoring distributed applications including an interface running in an operating system kernel 失效
标题翻译：用于监视分布式应用程序的系统和方法，包括在操作系统内核中运行的接口
公开(公告)号：US5958010A
公开(公告)日：1999-09-28
申请号：US821698
申请日：1997-03-20
申请人： Neeraj Agarwal , Pierre Perret , Michael G. McMenemy
发明人： Neeraj Agarwal , Pierre Perret , Michael G. McMenemy
IPC分类号： G06F11/30 , G06F9/46 , G06F13/00 , G06F15/16 , G06F15/177 , H04L12/26 , H04L29/14
CPC分类号： H04L43/12 , H04L43/0847
摘要： Systems and methods for automated monitoring and management of distributed applications, client/server databases, networks and systems across heterogeneous environment The invention employs distributed, automated intelligent monitoring agents with embedded sensing technology which is knowledgeable of application protocols, to monitor continuously the network environment in real time. To this end, the monitoring agent can be located on each client and server in the network. The monitoring agent can couple to the communications stack for monitoring the data that is being passed between the client and the network, of a server in the network. The data can be collected and employed for trouble shooting trend analysis, resource planning, security auditing, accounting and chargeback, as well as other applications.
摘要翻译：跨异构环境的分布式应用程序，客户端/服务器数据库，网络和系统的自动化监控和管理的系统和方法本发明采用具有嵌入式感知技术的分布式自动化智能监控代理，其具有应用协议知识，可以连续监视网络环境即时的。为此，监控代理可以位于网络中的每个客户端和服务器上。监视代理可以耦合到通信栈以监视网络中的服务器在客户端和网络之间传递的数据。数据可以收集并用于故障排除趋势分析，资源规划，安全审计，会计和退款以及其他应用。

2. 发明授权

US07186707B2 Prodrugs for use as ophthalmic agents 有权
标题翻译：用作眼科剂的前药
公开(公告)号：US07186707B2
公开(公告)日：2007-03-06
申请号：US10731528
申请日：2003-12-09
申请人： Laszlo Prokai , Katalin Prokai , James Simpkins , Neeraj Agarwal
发明人： Laszlo Prokai , Katalin Prokai , James Simpkins , Neeraj Agarwal
IPC分类号： A61K31/56 , C07J1/00
CPC分类号： A61K31/57 , A61K31/56 , A61K31/58 , C07J1/00
摘要： The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).
摘要翻译：本发明提供了一种使甾体喹啉化合物赋予有益的眼科效果的机制。本发明化合物具有用于经角膜穿透的亲脂亲水平衡，并且易于还原成亲本酚A型类固醇化合物以提供针对各种眼部症状和障碍的保护或治疗。根据本发明的化合物似乎是非常有利的作为前药以提供对眼部疾病的保护和/或治疗。这些前药赋予了对于经角膜穿透最佳的脂质溶解性并且容易地转化为内源性还原剂成活性酚A型类固醇化合物。在这些前药具有降低的女性化作用和全身毒性的程度上，预期它们对于保护或治疗眼睛免于眼部疾病如白内障或青光眼而没有不期望（全身）副作用）是非常有利的。

3. 发明授权

US06714976B1 Systems and methods for monitoring distributed applications using diagnostic information 有权
标题翻译：使用诊断信息监控分布式应用程序的系统和方法
公开(公告)号：US06714976B1
公开(公告)日：2004-03-30
申请号：US09368270
申请日：1999-08-03
申请人： James Wilson , Neeraj Agarwal , Gary Fernandez , Murtaza Doctor , Ken Kane , Albert Briner , Sehkar Muddana , Pieter deGroot , John Lyon-Smith , Scott Mendel
发明人： James Wilson , Neeraj Agarwal , Gary Fernandez , Murtaza Doctor , Ken Kane , Albert Briner , Sehkar Muddana , Pieter deGroot , John Lyon-Smith , Scott Mendel
IPC分类号： G06F15173
CPC分类号： H04L41/00 , H04L29/06 , H04L43/00 , H04L43/10 , H04L43/12 , H04L43/16 , H04L67/42
摘要： Systems and methods for automated monitoring and management of distributed applications, client/server databases, networks and systems across heterogeneous environments. Distributed, automated intelligent monitoring agents use embedded sensing technology which is knowledgeable of application protocols, to monitor continuously the network environment in real time. To this end, the monitoring agent can be located on each client and server in the network. The monitoring agent can couple to the communications stack for monitoring the data that is being passed between the client and the network, of a server in the network. The data can be collected and employed for trouble shooting trend analysis, resource planning, security auditing, and accounting as well as other applications. Also included is a controller for remotely coordinating the data gathering process from the various clients and servers.
摘要翻译：分布式应用程序，异构环境中的客户端/服务器数据库，网络和系统的自动监控和管理的系统和方法。分布式自动化智能监控代理使用了熟悉应用协议的嵌入式传感技术，实时监控网络环境。为此，监控代理可以位于网络中的每个客户端和服务器上。监视代理可以耦合到通信栈以监视网络中的服务器在客户端和网络之间传递的数据。数据可以收集并用于故障排除趋势分析，资源规划，安全审计，会计以及其他应用。还包括一个用于从各种客户端和服务器远程协调数据收集过程的控制器。

4. 发明授权

US07572781B2 Prodrugs for use as ophthalmic agents 有权
标题翻译：用作眼科剂的前药
公开(公告)号：US07572781B2
公开(公告)日：2009-08-11
申请号：US11706617
申请日：2007-02-15
申请人： Laszlo Prokai , Katalin Prokai , James Simpkins , Neeraj Agarwal
发明人： Laszlo Prokai , Katalin Prokai , James Simpkins , Neeraj Agarwal
IPC分类号： A61K31/56 , C07J1/00
CPC分类号： A61K31/57 , A61K31/56 , A61K31/58 , C07J1/00
摘要： The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).
摘要翻译：本发明提供了一种使甾体喹啉化合物赋予有益的眼科效果的机制。本发明化合物具有用于经角膜穿透的亲脂亲水平衡，并且易于还原成亲本酚A型类固醇化合物以提供针对各种眼部症状和障碍的保护或治疗。根据本发明的化合物似乎是非常有利的作为前药以提供对眼部疾病的保护和/或治疗。这些前药赋予了对于经角膜穿透最佳的脂质溶解性并且容易地转化为内源性还原剂成活性酚A型类固醇化合物。在这些前药具有降低的女性化作用和全身毒性的程度上，预期它们对于保护或治疗眼睛免于眼部疾病如白内障或青光眼而没有不期望（全身）副作用）是非常有利的。

5. 发明申请

US20070155711A1 Prodrugs for use as ophthalmic agents 有权
标题翻译：用作眼科剂的前药
公开(公告)号：US20070155711A1
公开(公告)日：2007-07-05
申请号：US11706617
申请日：2007-02-15
申请人： Laszlo Prokai , Katalin Prokai , James Simpkins , Neeraj Agarwal
发明人： Laszlo Prokai , Katalin Prokai , James Simpkins , Neeraj Agarwal
IPC分类号： A61K31/57
CPC分类号： A61K31/57 , A61K31/56 , A61K31/58 , C07J1/00
摘要： The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcomeal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocomeal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).
摘要翻译：本发明提供了一种使甾体喹啉化合物赋予有益的眼科效果的机制。主题化合物具有亲和亲水平衡，用于转导穿透，并且易于还原成亲本酚A型类固醇化合物，以提供针对各种眼部症状和障碍的保护或治疗。根据本发明的化合物似乎是非常有利的作为前药以提供对眼部疾病的保护和/或治疗。这些前体药物赋予脂质溶解度最佳用于经胚胎穿透，并且容易地转化为内源性还原剂成活性酚A型类固醇化合物。在这些前药具有降低的女性化作用和全身毒性的程度上，预期它们对于保护或治疗眼睛免于眼部疾病如白内障或青光眼而没有不期望（全身）副作用）是非常有利的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式